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. 4 If only genetically confirmed monogenic FH is considered, then the excess risk for PAD remains in these cohorts (OR: 2.96 [0.68-12.880]) but this is nonsignificant due to lower numbers. In the analysis, the risk of PAD was associated with disease severity as defined by a low-density lipoprotein cholesterol (LDL-C) >4. This analysis used cohort studies with control groups to ascertain risks of atheroma. Other excluded studies include the Simon Broome cohort study which has now been running for >20 years comprising 2871 patients and 22 992 patient-years of follow-up. 5 In that cohort where mortality data are used, a large excess of CAD events 6 is seen while strokes are less frequent than expected in FH with only 5% of deaths being due to stroke with a standardized mortality ratio of 0.79 (CI: 0.36-1.50). No data has been reported on PAD possibly as it is not often listed as a cause of death. Early studies in FH reported a high prevalence of PAD of up to 30% to 40% in patients with FH. 7 Later studies using peripheral arterial ultrasound assessment and ankle-brachial indices also showed a raised prevalence of subclinical PAD ranging from 30% to 65% but were limited by small numbers of subjects. 8, 9 A recent study in 202 patients with FH mostly with monogenic disease (total cholesterol 8.7 mmol/L; 336 mg/dL; 35% smokers) suggested 17% had PAD based on an ankle-brachial index <0.9. 10 Recent registry data from France identified PAD as the initial presentation in 9% of patients with FH and as a second event in 15% but did not detail original LDL-C or current rates of smoking. 11 The current study based on large cohorts is far more robust in showing an increased prevalence of PAD in FH in large assembled group of cohort studies. 4 Many reports confirm that CAD risk is strongly associated with high LDL-C in FH. 12 However, the findings of these studies that form the basis of this meta-analysis seem to be at variance with the practice of lipid clinics. While lipid clinics in the United Kingdom commonly see patients for diagnosis and management of FH, presentations with PAD seem to be rare as only 1% of presentations were for PAD. 13 Furthermore, as screening for FH becomes more common and genetic testing is introduced, cascade screening is becoming routine and the historical selection bias toward greater severity abates; thus rates of diagnosed CAD are falling in clinic FH populations. 14 The extent of referral bias can be seen in the fact that many reported clinic cohorts have untreated LDL-C 6.0-8.0 mmol/L (240-320 mg/dL) with a treated LDL-C around 4.5 mmol/L (180 mg/dL). The average LDL-C in general unselected FH populations based on untreated relatives is around 4.5 mmol/L (180 mg/dL) and is only moderately higher than that in the general population. 15 The prevalence of risk factors strongly associated with PAD is also changing. 16 Three are commonly recognized factorssmoking, type 2 diabetes, and raised lipoprotein (a) concentrations. 17 In wider society, rates of smoking are falling attenuating risks for CAD and likely more strongly for PAD given the stronger relationship of PAD with smoking. 16, 17 Rates of smoking are often lower in patients with FH than the general population with rates of 13% reported in a recent UK audit compared to up to 20% in the general population. 13 Diabetes is commonly associated with PAD 16, 17 and the prevalence of this disease is increasing in the general population in line with the occurrence of obesity, yet there is a suggestion that patients with FH may be protected against developing diabetes (OR: 0.62 [0.55-0.69]) compared to the general population. 18 Raised lipoprotein (a) concentrations are common in FH 19 and are independently associated with PAD but are predominantly genetically inherited. 17, 20 The presence of these factors suggest that PAD should be more common than is commonly thought in FH and this audit would tend to support that. 4 However, clinically this does not seem to be the case as presentations with claudication to lipid clinics seem to be infrequent. 11, 13 Whether an unrecognized referral bias exists that reduces rates of referrals to specialist lipid clinics from vascular surgery units in many centers remains to be explored but might be suspected given the results of this study.
Imaging has a long history in FH. Increased carotid intimamedia thickness (IMT) and carotid plaques are often found in patients with FH 21 though many centers now favor computerized tomographic coronary angiography or coronary artery calcium measurement for assessment of CAD. However, as high rates of symptomatic PAD do not seem to be common in lipid clinics systematic assessment of PAD through measurement of ankle-brachial indices or Doppler ultrasonography is often not performed. Yet, early signs of PAD on imaging are common in FH as data from clinical trials such as the AtorvastatinSimvastatin Atherosclerosis Prevention (ASAP) study which recruited a FH population with original LDL-C of 8 mmol/L (320 mg/dL) and treated to either 4.81 mmol/L (187 mg/dL; simvastatin 40 mg) or 3.81 mmol/L (147 mg/dL; atorvastatin 80 mg). 22 In ASAP, the baseline femoral IMT (FIMT) was 1.69 mm in the atorvastatin group and 1.61 mm in the simvastatin group; at 2 years, FIMT had increased by 0.06 mm (P ¼ .24) and 0.15 mm (P ¼ .012), respectively, paralleling changes seen in carotid IMT primary end point yet unlike in the carotids there was no significant difference between the 2 treatment arms (P ¼ .26). 23 Notably femoral plaques were present in 64.7% in the atorvastatin group and 56.1% in the simvastatin group at baseline with the prevalence rising after 2 years to 66.0% (P ¼ .47) and 67.3% (P ¼ .02), respectively, again with no significant differences with treatment allocation (P ¼ .87). 23 In contrast, carotid plaques were present in 6.3 versus 4.9% and after 2 years; these had changed little as plaque frequencies were 5.0% (P ¼ .48) versus 5.5% (P ¼ .71), respectively (P ¼ .90 between allocated treatments). This study showed that femoral plaque was very common in FH yet femoral ultrasonography in FH has never been widely implemented. If PAD is common in FH, then as these patients are at increased cardiovascular disease risk, 24 they would benefit from systematic investigation and more aggressive lipid management. This is recognized in some guidelines for prescription of proprotein convertase subtilisin kexin-9 inhibitors which allow prescribing at lower LDL-C levels (eg, <3.5 mmol/L [140 mg/ dL]) in patients with atherosclerotic disease in multiple vascular beds than with CAD alone (<4.00 mmol/L [160 mg/dL]). 25 Femoral artery plaque and potentially clinically significant PAD may be more common than previously suspected in FH. Studies are required in unselected primary care FH populations to ascertain the true frequency of PAD in FH.
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